KURA
Kura Oncology IncNASDAQHEALTHCAREBIOTECHNOLOGY
Key Statistics
Market Cap
$783.77M
P/E Ratio
—
EPS
$-3.18
Beta
0.24
52W High
$12.49
52W Low
$5.45
50-Day MA
$8.72
200-Day MA
$8.88
Dividend Yield
—
Profit Margin
0.00%
Forward P/E
—
PEG Ratio
0.00
About Kura Oncology Inc
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops drugs for the treatment of cancer in the United States. The company is headquartered in San Diego, California.
Fundamentals
| Revenue (TTM) | $67.48M |
| Gross Profit (TTM) | $-183.65M |
| EBITDA | $-302.60M |
| Operating Margin | -497.60% |
| Return on Equity | -94.80% |
| Return on Assets | -25.30% |
| Revenue/Share (TTM) | $0.77 |
| Book Value | $1.98 |
| Price-to-Book | 4.50 |
| Price-to-Sales (TTM) | 11.61 |
| EV/Revenue | 2.03 |
| EV/EBITDA | -2.48 |
| Quarterly Earnings Growth (YoY) | 0.00% |
| Quarterly Revenue Growth (YoY) | -67.80% |
| Shares Outstanding | $88.76M |
| Float | $64.96M |
| % Insiders | 1.45% |
| % Institutions | 96.56% |
Historical Volatility
HV 10-Day
51.71%
HV 20-Day
48.00%
HV 30-Day
51.28%
HV 60-Day
47.57%
HV Rank
23.8%
Volatility is currently expanding
Analyst Ratings
Consensus ($31.17 target)
2
Strong Buy11
Buy1
HoldData last updated: 4/29/2026